

Global Antisense Oligonucleotide Therapy for the Nervous System Market Growth (Status and Outlook) 2026-2032

<https://marketpublishers.com/r/GB4A9810A516EN.html>

Date: July 2026

Pages: 71

Price: US\$ 3,660.00 (Single User License)

ID: GB4A9810A516EN

Abstracts

The global Antisense Oligonucleotide Therapy for the Nervous System market size is predicted to grow from US\$ 4553 million in 2025 to US\$ 14190 million in 2032; it is expected to grow at a CAGR of 18.0% from 2026 to 2032.

Antisense Oligonucleotides (ASOs) are a class of nucleic acid drugs designed to target specific RNA molecules within cells. They work by binding to complementary RNA sequences, which can modulate gene expression in various ways. ASOs have been developed to treat a wide range of genetic and other diseases

United States market for Antisense Oligonucleotide Therapy for the Nervous System is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Antisense Oligonucleotide Therapy for the Nervous System is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Antisense Oligonucleotide Therapy for the Nervous System is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Antisense Oligonucleotide Therapy for the Nervous System players cover Ionis Pharmaceuticals, Biogen, Sobi, Nippon Shinyaku, Jazz Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LPI (LP Information)' newest research report, the 'Antisense Oligonucleotide Therapy for the Nervous System Industry Forecast' looks at past sales and reviews total world Antisense Oligonucleotide Therapy for the Nervous System sales in 2025, providing a comprehensive analysis by region and market sector of projected Antisense Oligonucleotide Therapy for the Nervous System sales for 2026 through 2032. With Antisense Oligonucleotide Therapy for the Nervous System sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Antisense Oligonucleotide Therapy for the Nervous System industry.

This Insight Report provides a comprehensive analysis of the global Antisense Oligonucleotide Therapy for the Nervous System landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Antisense Oligonucleotide Therapy for the Nervous System portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Antisense Oligonucleotide Therapy for the Nervous System market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antisense Oligonucleotide Therapy for the Nervous System and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antisense Oligonucleotide Therapy for the Nervous System.

This report presents a comprehensive overview, market shares, and growth opportunities of Antisense Oligonucleotide Therapy for the Nervous System market by product type, application, key players and key regions and countries.

Segmentation by Type:

Intrathecal Injection

Intravenous Injections

Other

Segmentation by Application:

Neuromuscular Diseases

hATTR

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Ionis Pharmaceuticals

Biogen

Sobi

Nippon Shinyaku

Jazz Pharmaceuticals

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Antisense Oligonucleotide Therapy for the Nervous System Market Size (2021-2032)

- 2.1.2 Antisense Oligonucleotide Therapy for the Nervous System Market Size CAGR by Region (2021 VS 2025 VS 2032)

- 2.1.3 World Current & Future Analysis for Antisense Oligonucleotide Therapy for the Nervous System by Country/Region (2021, 2025 & 2032)

2.2 Antisense Oligonucleotide Therapy for the Nervous System Segment by Type

- 2.2.1 Intrathecal Injection

- 2.2.2 Intravenous Injections

- 2.2.3 Other

- 2.2.4 Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type

- 2.2.4.1 Antisense Oligonucleotide Therapy for the Nervous System Market Size CAGR by Type (2021 VS 2025 VS 2032)

- 2.2.4.2 Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Type (2021-2026)

2.3 Antisense Oligonucleotide Therapy for the Nervous System Segment by Application

- 2.3.1 Neuromuscular Diseases

- 2.3.2 hATTR

- 2.3.3 Other

- 2.3.4 Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application

- 2.3.4.1 Antisense Oligonucleotide Therapy for the Nervous System Market Size CAGR by Application (2021 VS 2025 VS 2032)

2.3.4.2 Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Application (2021-2026)

3 ANTISENSE OLIGONUCLEOTIDE THERAPY FOR THE NERVOUS SYSTEM MARKET SIZE BY PLAYER

3.1 Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Player

3.1.1 Global Antisense Oligonucleotide Therapy for the Nervous System Revenue by Player (2021-2026)

3.1.2 Global Antisense Oligonucleotide Therapy for the Nervous System Revenue Market Share by Player (2021-2026)

3.2 Global Antisense Oligonucleotide Therapy for the Nervous System Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 ANTISENSE OLIGONUCLEOTIDE THERAPY FOR THE NERVOUS SYSTEM BY REGION

4.1 Antisense Oligonucleotide Therapy for the Nervous System Market Size by Region (2021-2026)

4.2 Global Antisense Oligonucleotide Therapy for the Nervous System Annual Revenue by Country/Region (2021-2026)

4.3 Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth (2021-2026)

4.4 APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth (2021-2026)

4.5 Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth (2021-2026)

4.6 Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth (2021-2026)

5 AMERICAS

5.1 Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size

by Country (2021-2026)

5.2 Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2021-2026)

5.3 Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size by Region (2021-2026)

6.2 APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2021-2026)

6.3 APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 EUROPE

7.1 Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2021-2026)

7.2 Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2021-2026)

7.3 Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System by Region (2021-2026)

8.2 Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2021-2026)

8.3 Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 GLOBAL ANTISENSE OLIGONUCLEOTIDE THERAPY FOR THE NERVOUS SYSTEM MARKET FORECAST

10.1 Global Antisense Oligonucleotide Therapy for the Nervous System Forecast by Region (2027-2032)

10.1.1 Global Antisense Oligonucleotide Therapy for the Nervous System Forecast by Region (2027-2032)

10.1.2 Americas Antisense Oligonucleotide Therapy for the Nervous System Forecast

10.1.3 APAC Antisense Oligonucleotide Therapy for the Nervous System Forecast

10.1.4 Europe Antisense Oligonucleotide Therapy for the Nervous System Forecast

10.1.5 Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Forecast

10.2 Americas Antisense Oligonucleotide Therapy for the Nervous System Forecast by Country (2027-2032)

10.2.1 United States Market Antisense Oligonucleotide Therapy for the Nervous System Forecast

10.2.2 Canada Market Antisense Oligonucleotide Therapy for the Nervous System Forecast

10.2.3 Mexico Market Antisense Oligonucleotide Therapy for the Nervous System

Forecast

10.2.4 Brazil Market Antisense Oligonucleotide Therapy for the Nervous System

Forecast

10.3 APAC Antisense Oligonucleotide Therapy for the Nervous System Forecast by Region (2027-2032)

10.3.1 China Antisense Oligonucleotide Therapy for the Nervous System Market

Forecast

10.3.2 Japan Market Antisense Oligonucleotide Therapy for the Nervous System

Forecast

10.3.3 Korea Market Antisense Oligonucleotide Therapy for the Nervous System

Forecast

10.3.4 Southeast Asia Market Antisense Oligonucleotide Therapy for the Nervous System Forecast

10.3.5 India Market Antisense Oligonucleotide Therapy for the Nervous System

Forecast

10.3.6 Australia Market Antisense Oligonucleotide Therapy for the Nervous System

Forecast

10.4 Europe Antisense Oligonucleotide Therapy for the Nervous System Forecast by Country (2027-2032)

10.4.1 Germany Market Antisense Oligonucleotide Therapy for the Nervous System

Forecast

10.4.2 France Market Antisense Oligonucleotide Therapy for the Nervous System

Forecast

10.4.3 UK Market Antisense Oligonucleotide Therapy for the Nervous System

Forecast

10.4.4 Italy Market Antisense Oligonucleotide Therapy for the Nervous System

Forecast

10.4.5 Russia Market Antisense Oligonucleotide Therapy for the Nervous System

Forecast

10.5 Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Forecast by Region (2027-2032)

10.5.1 Egypt Market Antisense Oligonucleotide Therapy for the Nervous System

Forecast

10.5.2 South Africa Market Antisense Oligonucleotide Therapy for the Nervous System

Forecast

10.5.3 Israel Market Antisense Oligonucleotide Therapy for the Nervous System

Forecast

10.5.4 Turkey Market Antisense Oligonucleotide Therapy for the Nervous System

Forecast

10.6 Global Antisense Oligonucleotide Therapy for the Nervous System Forecast by Type (2027-2032)

10.7 Global Antisense Oligonucleotide Therapy for the Nervous System Forecast by Application (2027-2032)

10.7.1 GCC Countries Market Antisense Oligonucleotide Therapy for the Nervous System Forecast

11 KEY PLAYERS ANALYSIS

11.1 Ionis Pharmaceuticals

11.1.1 Ionis Pharmaceuticals Company Information

11.1.2 Ionis Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Product Offered

11.1.3 Ionis Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Revenue, Gross Margin and Market Share (2021-2026)

11.1.4 Ionis Pharmaceuticals Main Business Overview

11.1.5 Ionis Pharmaceuticals Latest Developments

11.2 Biogen

11.2.1 Biogen Company Information

11.2.2 Biogen Antisense Oligonucleotide Therapy for the Nervous System Product Offered

11.2.3 Biogen Antisense Oligonucleotide Therapy for the Nervous System Revenue, Gross Margin and Market Share (2021-2026)

11.2.4 Biogen Main Business Overview

11.2.5 Biogen Latest Developments

11.3 Sobi

11.3.1 Sobi Company Information

11.3.2 Sobi Antisense Oligonucleotide Therapy for the Nervous System Product Offered

11.3.3 Sobi Antisense Oligonucleotide Therapy for the Nervous System Revenue, Gross Margin and Market Share (2021-2026)

11.3.4 Sobi Main Business Overview

11.3.5 Sobi Latest Developments

11.4 Nippon Shinyaku

11.4.1 Nippon Shinyaku Company Information

11.4.2 Nippon Shinyaku Antisense Oligonucleotide Therapy for the Nervous System Product Offered

11.4.3 Nippon Shinyaku Antisense Oligonucleotide Therapy for the Nervous System Revenue, Gross Margin and Market Share (2021-2026)

11.4.4 Nippon Shinyaku Main Business Overview

11.4.5 Nippon Shinyaku Latest Developments

11.5 Jazz Pharmaceuticals

11.5.1 Jazz Pharmaceuticals Company Information

11.5.2 Jazz Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Product Offered

11.5.3 Jazz Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Revenue, Gross Margin and Market Share (2021-2026)

11.5.4 Jazz Pharmaceuticals Main Business Overview

11.5.5 Jazz Pharmaceuticals Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Antisense Oligonucleotide Therapy for the Nervous System Market Size CAGR by Region (2021 VS 2025 VS 2032) & (\$ millions)

Table 2. Antisense Oligonucleotide Therapy for the Nervous System Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Intrathecal Injection

Table 4. Major Players of Intravenous Injections

Table 5. Major Players of Other

Table 6. Antisense Oligonucleotide Therapy for the Nervous System Market Size CAGR by Type (2021 VS 2025 VS 2032) & (\$ millions)

Table 7. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2021-2026) & (\$ millions)

Table 8. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Type (2021-2026)

Table 9. Antisense Oligonucleotide Therapy for the Nervous System Market Size CAGR by Application (2021 VS 2025 VS 2032) & (\$ millions)

Table 10. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2021-2026) & (\$ millions)

Table 11. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Application (2021-2026)

Table 12. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue by Player (2021-2026) & (\$ millions)

Table 13. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue Market Share by Player (2021-2026)

Table 14. Antisense Oligonucleotide Therapy for the Nervous System Key Players Head office and Products Offered

Table 15. Antisense Oligonucleotide Therapy for the Nervous System Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 16. New Products and Potential Entrants

Table 17. Mergers & Acquisitions, Expansion

Table 18. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size by Region (2021-2026) & (\$ millions)

Table 19. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Region (2021-2026)

Table 20. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue by Country/Region (2021-2026) & (\$ millions)

Table 21. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue Market Share by Country/Region (2021-2026)

Table 22. Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2021-2026) & (\$ millions)

Table 23. Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Country (2021-2026)

Table 24. Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2021-2026) & (\$ millions)

Table 25. Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Type (2021-2026)

Table 26. Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2021-2026) & (\$ millions)

Table 27. Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Application (2021-2026)

Table 28. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size by Region (2021-2026) & (\$ millions)

Table 29. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Region (2021-2026)

Table 30. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2021-2026) & (\$ millions)

Table 31. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2021-2026) & (\$ millions)

Table 32. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2021-2026) & (\$ millions)

Table 33. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Country (2021-2026)

Table 34. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2021-2026) & (\$ millions)

Table 35. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2021-2026) & (\$ millions)

Table 36. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size by Region (2021-2026) & (\$ millions)

Table 37. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2021-2026) & (\$ millions)

Table 38. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2021-2026) & (\$ millions)

Table 39. Key Market Drivers & Growth Opportunities of Antisense Oligonucleotide Therapy for the Nervous System

Table 40. Key Market Challenges & Risks of Antisense Oligonucleotide Therapy for the

Nervous System

Table 41. Key Industry Trends of Antisense Oligonucleotide Therapy for the Nervous System

Table 42. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Forecast by Region (2027-2032) & (\$ millions)

Table 43. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share Forecast by Region (2027-2032)

Table 44. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Forecast by Type (2027-2032) & (\$ millions)

Table 45. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Forecast by Application (2027-2032) & (\$ millions)

Table 46. Ionis Pharmaceuticals Details, Company Type, Antisense Oligonucleotide Therapy for the Nervous System Area Served and Its Competitors

Table 47. Ionis Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Product Offered

Table 48. Ionis Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 49. Ionis Pharmaceuticals Main Business

Table 50. Ionis Pharmaceuticals Latest Developments

Table 51. Biogen Details, Company Type, Antisense Oligonucleotide Therapy for the Nervous System Area Served and Its Competitors

Table 52. Biogen Antisense Oligonucleotide Therapy for the Nervous System Product Offered

Table 53. Biogen Antisense Oligonucleotide Therapy for the Nervous System Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 54. Biogen Main Business

Table 55. Biogen Latest Developments

Table 56. Sobi Details, Company Type, Antisense Oligonucleotide Therapy for the Nervous System Area Served and Its Competitors

Table 57. Sobi Antisense Oligonucleotide Therapy for the Nervous System Product Offered

Table 58. Sobi Antisense Oligonucleotide Therapy for the Nervous System Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 59. Sobi Main Business

Table 60. Sobi Latest Developments

Table 61. Nippon Shinyaku Details, Company Type, Antisense Oligonucleotide Therapy for the Nervous System Area Served and Its Competitors

Table 62. Nippon Shinyaku Antisense Oligonucleotide Therapy for the Nervous System Product Offered

Table 63. Nippon Shinyaku Antisense Oligonucleotide Therapy for the Nervous System Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 64. Nippon Shinyaku Main Business

Table 65. Nippon Shinyaku Latest Developments

Table 66. Jazz Pharmaceuticals Details, Company Type, Antisense Oligonucleotide Therapy for the Nervous System Area Served and Its Competitors

Table 67. Jazz Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Product Offered

Table 68. Jazz Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 69. Jazz Pharmaceuticals Main Business

Table 70. Jazz Pharmaceuticals Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Antisense Oligonucleotide Therapy for the Nervous System Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth Rate (2021-2032) (\$ millions)

Figure 6. Antisense Oligonucleotide Therapy for the Nervous System Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 7. Antisense Oligonucleotide Therapy for the Nervous System Sales Market Share by Country/Region (2025)

Figure 8. Antisense Oligonucleotide Therapy for the Nervous System Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 9. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Type in 2025

Figure 10. Antisense Oligonucleotide Therapy for the Nervous System in Neuromuscular Diseases

Figure 11. Global Antisense Oligonucleotide Therapy for the Nervous System Market: Neuromuscular Diseases (2021-2026) & (\$ millions)

Figure 12. Antisense Oligonucleotide Therapy for the Nervous System in hATTR

Figure 13. Global Antisense Oligonucleotide Therapy for the Nervous System Market: hATTR (2021-2026) & (\$ millions)

Figure 14. Antisense Oligonucleotide Therapy for the Nervous System in Other

Figure 15. Global Antisense Oligonucleotide Therapy for the Nervous System Market: Other (2021-2026) & (\$ millions)

Figure 16. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Application in 2025

Figure 17. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue Market Share by Player in 2025

Figure 18. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Region (2021-2026)

Figure 19. Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size 2021-2026 (\$ millions)

Figure 20. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size 2021-2026 (\$ millions)

Figure 21. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size 2021-2026 (\$ millions)

Figure 22. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size 2021-2026 (\$ millions)

Figure 23. Americas Antisense Oligonucleotide Therapy for the Nervous System Value Market Share by Country in 2025

Figure 24. United States Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2021-2026 (\$ millions)

Figure 25. Canada Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2021-2026 (\$ millions)

Figure 26. Mexico Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2021-2026 (\$ millions)

Figure 27. Brazil Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2021-2026 (\$ millions)

Figure 28. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Region in 2025

Figure 29. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Type (2021-2026)

Figure 30. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Application (2021-2026)

Figure 31. China Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2021-2026 (\$ millions)

Figure 32. Japan Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2021-2026 (\$ millions)

Figure 33. South Korea Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2021-2026 (\$ millions)

Figure 34. Southeast Asia Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2021-2026 (\$ millions)

Figure 35. India Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2021-2026 (\$ millions)

Figure 36. Australia Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2021-2026 (\$ millions)

Figure 37. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Country in 2025

Figure 38. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Type (2021-2026)

Figure 39. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Application (2021-2026)

Figure 40. Germany Antisense Oligonucleotide Therapy for the Nervous System Market

Size Growth 2021-2026 (\$ millions)

Figure 41. France Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2021-2026 (\$ millions)

Figure 42. UK Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2021-2026 (\$ millions)

Figure 43. Italy Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2021-2026 (\$ millions)

Figure 44. Russia Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2021-2026 (\$ millions)

Figure 45. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Region (2021-2026)

Figure 46. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Type (2021-2026)

Figure 47. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Application (2021-2026)

Figure 48. Egypt Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2021-2026 (\$ millions)

Figure 49. South Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2021-2026 (\$ millions)

Figure 50. Israel Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2021-2026 (\$ millions)

Figure 51. Turkey Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2021-2026 (\$ millions)

Figure 52. GCC Countries Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2021-2026 (\$ millions)

Figure 53. Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size 2027-2032 (\$ millions)

Figure 54. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size 2027-2032 (\$ millions)

Figure 55. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size 2027-2032 (\$ millions)

Figure 56. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size 2027-2032 (\$ millions)

Figure 57. United States Antisense Oligonucleotide Therapy for the Nervous System Market Size 2027-2032 (\$ millions)

Figure 58. Canada Antisense Oligonucleotide Therapy for the Nervous System Market Size 2027-2032 (\$ millions)

Figure 59. Mexico Antisense Oligonucleotide Therapy for the Nervous System Market Size 2027-2032 (\$ millions)

Figure 60. Brazil Antisense Oligonucleotide Therapy for the Nervous System Market Size 2027-2032 (\$ millions)

Figure 61. China Antisense Oligonucleotide Therapy for the Nervous System Market Size 2027-2032 (\$ millions)

Figure 62. Japan Antisense Oligonucleotide Therapy for the Nervous System Market Size 2027-2032 (\$ millions)

Figure 63. Korea Antisense Oligonucleotide Therapy for the Nervous System Market Size 2027-2032 (\$ millions)

Figure 64. Southeast Asia Antisense Oligonucleotide Therapy for the Nervous System Market Size 2027-2032 (\$ millions)

Figure 65. India Antisense Oligonucleotide Therapy for the Nervous System Market Size 2027-2032 (\$ millions)

Figure 66. Australia Antisense Oligonucleotide Therapy for the Nervous System Market Size 2027-2032 (\$ millions)

Figure 67. Germany Antisense Oligonucleotide Therapy for the Nervous System Market Size 2027-2032 (\$ millions)

Figure 68. France Antisense Oligonucleotide Therapy for the Nervous System Market Size 2027-2032 (\$ millions)

Figure 69. UK Antisense Oligonucleotide Therapy for the Nervous System Market Size 2027-2032 (\$ millions)

Figure 70. Italy Antisense Oligonucleotide Therapy for the Nervous System Market Size 2027-2032 (\$ millions)

Figure 71. Russia Antisense Oligonucleotide Therapy for the Nervous System Market Size 2027-2032 (\$ millions)

Figure 72. Egypt Antisense Oligonucleotide Therapy for the Nervous System Market Size 2027-2032 (\$ millions)

Figure 73. South Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size 2027-2032 (\$ millions)

Figure 74. Israel Antisense Oligonucleotide Therapy for the Nervous System Market Size 2027-2032 (\$ millions)

Figure 75. Turkey Antisense Oligonucleotide Therapy for the Nervous System Market Size 2027-2032 (\$ millions)

Figure 76. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share Forecast by Type (2027-2032)

Figure 77. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share Forecast by Application (2027-2032)

Figure 78. GCC Countries Antisense Oligonucleotide Therapy for the Nervous System Market Size 2027-2032 (\$ millions)

I would like to order

Product name: Global Antisense Oligonucleotide Therapy for the Nervous System Market Growth (Status and Outlook) 2026-2032

Product link: <https://marketpublishers.com/r/GB4A9810A516EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB4A9810A516EN.html>